



Parental comprehension of the benefits/risks of first line randomized clinical trials in children with solid tumors

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002733
Article Type:	Research
Date Submitted by the Author:	15-Feb-2013
Complete List of Authors:	Chappuy, H�el�ene; H�opital Necker Enfants Malades, Pediatric emergency department Bouazza, Naim; APHP, Unit� de Recherche Clinique Minard-Colin, Veronique; Institut Gustave Roussy, Department of Pediatric and Adolescent Oncology Patte, Catherine; Institut Gustave Roussy, Department of Pediatric and Adolescent Oncology Brugi�eres, Laurence; Institut Gustave Roussy, Department of Pediatric and Adolescent Oncology Landman-Parker, Judith; H�opital Armand Trousseau, Departement of Pediatric Oncology Auvrignon, Anne; H�opital Armand Trousseau, Departement of Pediatric Oncology Davous, Dominique; Association Apprivoiser l'absence, Cent pour Sang la Vie, Pacquement, H�el�ene; Institut Curie, Department of Pediatric Oncology Orbach, Daniel; Institut Curie, Department of Pediatric Oncology Tr�eluyer, Jean Marc; APHP, Pharmacology Doz, Fran�ois; Institut Curie, Department of Pediatric Oncology
Primary Subject Heading:	Ethics
Secondary Subject Heading:	Oncology, Paediatrics
Keywords:	MEDICAL ETHICS, Paediatric oncology < ONCOLOGY, MEDICAL LAW

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Parental comprehension of the benefits/risks of first line randomized clinical trials in children with solid tumors

Key words: child, neoplasm, randomized clinical trial, informed consent

Words count: 3077

For peer review only

Abstract

Background: To analyze parental understanding of informed consent (IC) information in randomized clinical trials (RCTs) including children with malignant solid tumors and to assess parents' needs for decision-making.

Methods: We carried out a prospective study including parents of children with malignant solid tumors whose consent was sought for the participation of their child in RCTs at three centers. Parents were questioned by a psychologist, independent of the pediatric oncology teams, using a semi-directed interview, one (M1) and six months (M6) after consent was sought.

Results: Forty first interviews were carried out. Eighteen parents (45%) did not understand the concept of randomization. Half of the parents could explain neither the aim of the clinical trial nor the potential benefit to their child of inclusion. Thirty-five parents (87.5%) recalled very few specific risks related to the trial. Twenty-eight parents (70%) were aware that they had the opportunity to refuse trial participation. Being mostly French-speaking ($p=0.03$) and the reading of the information sheet by the parents ($p=0.0025$) improved their understanding. The parental comprehension did not differ between M1 and M6. The principal factors underlying their decision were confidence in the medical team (39%), wish to access to the best treatment (37%) and the best quality of life (37%).

Conclusions: Despite medical explanations, parents have limited knowledge in some areas in RCTs and improvements of information process are required. The risks specific to the randomized trial are underestimated by parents and the unproven nature of the treatment is not well known or understood.

ARTICLE SUMMARY

Article focus

- We analyze parental understanding of oral and written information in randomized clinical trials (RCTs) including children with varied solid tumors, and focus more specifically on parental comprehension of the potential (or expected) benefits to their child of inclusion in a RCT.
- We identify parental needs for decision-making.
- The parents were seen twice, by a qualified psychologist: one month after they were asked to participate in the RCT and then again, six months later.

Key messages

- Most parents had understood the general aspects, by contrast, less than half the parents had correctly understood the more specific information such as the aims of the study, randomization, the various phases of treatment and the risks specific to the randomized trial.
- Parents tend to underestimate risks specific to the randomized trial and the unproven nature of the treatment is not well known or understood.
- Quality of life is a crucial element in the decision of parents to agree to the participation of their child in a randomized phase 3 trial.

Strengths and limitations of this study

- We have data that reflect the full spectrum of pediatric oncology clinical research, including children with solid or brain tumors whereas most of the available pediatric data are related to research for newly diagnosed acute leukaemia.
- The understanding of some components of informed consent may be equivalent to recall. However, the parents were asked to participate in this study soon after giving consent for the participation of their child in a clinical trial.

INTRODUCTION

Cancers occur before the age of 15 years in one in every 500 children and 1700 new cases are recorded each year for this age group in French registries (<http://sfce1.sfpediatric.com/>).

Although global cure rates in pediatric cancers today achieve 80% in western countries, cancers are still the second leading cause of death in children between 1 and 15 years, after accidents. The optimization of treatment in pediatric oncology is desirable not only to continue to improve cure rates but also to decrease late effects. In this setting, randomized clinical trials (RCTs) to test new treatment options are essential in pediatric oncology.

However, the patients participating in a trial might not benefit directly themselves; instead, the outcome of the studies provides information about future treatment options. Patients and their parents must, therefore, necessarily receive appropriate information about the possible risks and the uncertain nature of the benefits of participation, to allow them to make truly autonomous decisions about participation in trials. They also require adequate information concerning crucial aspects of RCTs if they are to make an informed decision. However, published findings indicate that parents or patients often misunderstand the research to which they consent.[1-4] Furthermore, most of the available pediatric data on the information process in the context of phase 3 trials in oncology are related to research for newly diagnosed acute leukaemia, [5-7] few data are available that reflect the full spectrum of pediatric oncology clinical research, including children with solid or brain tumors.

The primary aim of this study was to analyze parental understanding of oral and written information in RCTs including children with varied solid tumors. The secondary aim was to assess the parents' statements in order to identify parental needs for decision-making.

METHODS

Sample population

This prospective study was carried out in the oncology departments of the three pediatric oncology centers in the Parisian region: Institut Curie (Paris), Institut Gustave Roussy (Villejuif), Hôpital Armand Trousseau (Paris). This study was approved by the appropriate institutional review board (*Comité de Protection des Personnes Ile de France III Hôpital Cochin*). The parents from these three centers who had been asked to give consent for the participation of their child in a phase 3 randomized trial were included in this study, over a one-year period. The doctors provided the parents with a copy of the information and consent forms and a summary diagram of the various phases of the research protocol. To avoid bias due to the assessment only of patients with a positive attitude to RCTs, we also included parents of children that had declined to participate in the trial. The characteristics of these randomized phase 3 trial protocols are described in table 1: most were trials aiming to decrease the toxicity of treatment without affecting its efficacy. With the agreement of physicians participating in the study, the physician seeking parental consent suggested participation in our study to the parents. Non inclusion criteria included consent in a language other than French. Families agreeing to participate were seen at the time of a planned consultation during routine follow-up or at the time of a hospital admission in order to minimise the additional constraints (time and travel) imposed on the parents.

Instrument

The parents were seen twice, by a qualified psychologist: one month after they were asked to participate in the study (M1) and then again, six months later (M6). These interviews took place on site and were recorded and retranscribed in their entirety. The parents were allowed to express themselves freely, in the framework of a semi-directed interview, in response to standardized questions. The structure for the semi-directed interviews was developed in

1
2
3 collaboration with psychologists, the parent of a former patient representing a patients'
4
5 association and some of the investigating doctors from the centers participating in this study.
6
7 This structure has been validated in previous studies.[5,8] The interview covered various
8
9 aspects of informed consent (IC): we evaluated parental comprehension based on the 11
10
11 elements included in the information sheet for each protocol. The questions asked to assess
12
13 parental comprehension are described in table 2.
14

15
16 We tried to identify elements predictive of a good understanding of the information provided
17
18 at the time at which consent was sought: parental socioprofessional category (high
19
20 standing/intermediate status/no profession), the principal language spoken, whether the
21
22 information document was read by the parents (yes/no), personal efforts to find information
23
24 (yes/no). We used the following questions to determine the reasons for which the parents had
25
26 given their consent: "How difficult was it to take the decision you took concerning the
27
28 participation of your child in this protocol?", "What were the principal elements underlying
29
30 your decision?", "Who do you feel took the final decision?" and "What do you expect from
31
32 the doctor?".
33
34

35 36 **Data analysis**

37
38 Each interview was independently coded by two psychologists, with the coding reviewed by a
39
40 pediatrician in cases of disagreement. Comprehension was classified as "complete", "partial"
41
42 or "null" for each element if all, some or none of the information sheet was recalled and
43
44 expressed by the parents. When considering risks, only those specific to the randomized trial
45
46 were considered (table 1). To test the influence of covariates on comprehension, partial and
47
48 complete comprehension were pooled for each of the 11 elements and compared with the
49
50 absence of comprehension. We evaluated the influence of the covariates on the percentage of
51
52 the elements understood by the parents. A mixed effects model taking into account the subject
53
54 and items as crossed random effects was used to assessed the stability of parental
55
56
57
58
59
60

1
2
3 comprehension between the two interviews at M1 and M6. The data collected were put into
4
5 an Access database. The results are expressed as percentages, means and standard deviations,
6
7 medians and ranges. Chi² tests were carried out to compare qualitative values, *t* tests were
8
9 used to compare quantitative values (normality assumption was checked by quantile-quantile
10
11 plots and Shapiro-Wilks' test) and logistic regression analyses were carried out to assess the
12
13 influence of covariates. Agreement between the two psychologists was assessed with a
14
15 weighted kappa reliability test for ordered data.
16
17
18
19

20 21 **RESULTS**

22
23 We carried out 40 first interviews, including four with parents who declined participation in a
24
25 randomized phase 3 trial (one child with medulloblastoma, one with hepatoblastoma and two
26
27 with retinoblastoma). We interviewed 37 mothers and 20 fathers (17 couples, 3 men attending
28
29 alone and 20 women alone). We carried out 32 second interviews: four of the original
30
31 interviewees (or couples) declined a second interview and four others were lost to follow-up
32
33 for this study (management continued at another center). We interviewed 25 mothers and 14
34
35 fathers (7 couples, 7 men attending alone and 18 women alone). We considered the responses
36
37 of each of the couples as if they were individuals (i.e. below, "parent" refers to the mother,
38
39 father or couple interviewed). Regarding the values of weighted kappa obtained, 0.84 [95%
40
41 CI: 0.72 - 0.90] and 0.93 [95% CI: 0.85 - 0.96], for M1 and M6 respectively, there was a high
42
43 degree of agreement between the two psychologists about the coding of each interview. The
44
45 characteristics of the study group are summarized in Table 3.
46
47
48

49
50 In 64% of cases, information about the protocol had been provided by a single doctor, to both
51
52 parents simultaneously in 91% of these cases. Twenty-seven parents (68%) had reread the
53
54 information document. When asked if they had looked for information themselves, 13 parents
55
56 (32.5%) said they had not done so, while others (67.5%) having mostly (24/40) searched for
57
58
59
60

1
2
3 information about the disease rather than about the randomized clinical trial (7/40). Internet
4
5 was the principal source of information for these parents.
6

7 8 **Parental comprehension**

9
10 At the first interview, six parents (15%) confused consent for care with consent for research.
11
12 Each of these cases of confusion concerned a different protocol. Thirteen of the parents
13
14 (34.2%) did not know that randomization had occurred and five (13.2%) knew that
15
16 randomization existed but could not explain it clearly. When asked about the risks specific to
17
18 the randomized trial, four parents (10%) were unable to cite a single risk, 35 parents (87.5%)
19
20 were able to cite less than half the risks and one parent (2.5%) was able to cite more than half
21
22 the risks.
23

24
25 The results of the second interviews were compared with those of the first interview: the level
26
27 of parental comprehension did not differ markedly between M1 and M6 ($p=0.5$). Figure 1
28
29 summarizes the comprehension of the 11 elements described in the methods for the two
30
31 interviews.
32

33
34 As far as the benefit to their children was concerned, parents giving a different response from
35
36 that indicated in the information document (1st interview, 35% of parents/2nd interview, 11.1%
37
38 of parents) expressed other aspects of the benefits anticipated for their child. Some felt there
39
40 was a benefit in terms of quality of life (less time spent in hospital, fewer displacements),
41
42 decreasing the amount of time for which their child would not attend school:
43

44
45 *“I think I would have had to stay here all day and he would have had to have two*
46
47 *sessions, but he wanted to go to school and that’s why he preferred to do it in one*
48
49 *go.”*, *“because the old treatment takes three days and this one only takes one day, so*
50
51 *for that reason alone, it’s better for him in my opinion.”*
52

53
54 Other parents had hopes of beneficial effects in terms of their child being cured:

55
56 *“Anyway, for him, if it’s beneficial he’s cured...and that’s the most important thing.”*
57
58
59
60

1
2
3 Some parents expressed notions of altruism:

4
5 *“Their aim and our aim are the same, because their goal is to progress in their*
6 *studies, to save children...”*, *“C. has benefited from what went before and so he*
7 *should help those who will come after him too.”*
8
9
10

11 Finally, some parents agreed to participation because they saw the research protocol as
12 providing access to better follow-up than they would have obtained with the standard
13 treatment:
14
15

16
17 *“We were told, relatively clearly, that children who followed research protocols... I’m*
18 *not saying that the others are neglected....but they are possibly followed a bit more*
19 *closely than children given the classic treatment, because of the phenomenon of data*
20 *collection for research.”*
21
22
23
24
25
26

27 If we look more closely at the responses of the four parents who refused to allow the
28 participation of their children in a research protocol, they had no notion of an expected benefit
29 for their child (*“Yes but I don’t see why it’s beneficial for him, because in some ways it’s still*
30 *being evaluated”*), or the traveling required represented too great a constraint for the parents.
31
32 Fluency in French ($p=0.03$) and reading the information notice ($p=0.0025$) were the only
33 covariates tested that significantly increased parental comprehension (table 4).
34
35

36 **Reasons for participation and physician’s influence on the decision to participate**

37
38 When asked how they felt about taking this decision, 24 parents (60%) said that they felt it
39 was “a logical decision” and 10 parents (25%) said that they had found it difficult. The others
40 said that they weren’t really “ready” to take a decision. In response to the question about the
41 elements guiding the decision, the most frequently given answers were confidence in the
42 medical team ($n=15$, 39%), access to the best possible treatment for the child ($n=14$, 37%) and
43 improvements in quality of life ($n=14$, 37%). Most of the parents ($n=34$, 85%) said that they
44 had taken the decision together, whereas the others had shared the task of decision-making
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with the doctor ($n=1$, 2.5%) or with the child ($n=5$, 12.5%). The parents expected the
4
5 following of the doctor: communication (17/22, 77%), sincerity (11/22, 50%), availability
6
7 (11/22, 50%), humanity (7/22, 32%) and competence (7/22, 32%).
8
9

10 11 **DISCUSSION**

12
13
14 Ideally, parents giving consent for inclusion in a randomized clinical trial should have
15
16 understood all the elements required by law to protect the participant. In reality, parental
17
18 comprehension is highly variable and depends on the elements considered. Most parents had
19
20 understood the general aspects, such as the potential benefit to other children, the nature of
21
22 the study (a clinical trial), the notion of voluntary participation, the duration of participation,
23
24 the alternatives opened to them and the possibility of withdrawal at any time. By contrast,
25
26 less than half the parents had correctly understood the more specific information, such as the
27
28 aims of the study, randomization, the various phases of treatment and the risks specific to the
29
30 randomized trial. These results are similar to published findings.[1,2,5,9] For example, for
31
32 randomization in our study, some of the parents had views about the best “arm” for their
33
34 child: some preferred the standard treatment, which they considered to be less risky,[10]
35
36 whereas others were disappointed that their child was in the standard treatment arm because
37
38 they could not see the point of having consented to participation in the study.[11] We wished
39
40 to focus more specifically on parental comprehension of the potential (or expected) benefits to
41
42 their child of inclusion in a randomized phase 3 research protocol. Indeed, less than one third
43
44 of the parents were able to describe specifically the potential benefits to their child, as stated
45
46 in the information document. In a recent study, Tait *et al.* [12] showed, through the use of
47
48 scenarios, that only a quarter of the parents had fully understood the benefits to their child,
49
50 and comprehension was even lower for studies of treatments with efficacy levels similar to
51
52 those of the standard treatment, but lower expected toxicity. In our study, the parents
53
54
55
56
57
58
59
60

1
2
3 expressed other expectations, such as benefits in terms of quality of life (less time spent in
4 hospital, fewer displacements), resulting in fewer hours of absence from school. This aspect
5 of the perception of the benefits anticipated by parents has been identified before, in phase I
6 trials in adults.[13,14] Other parents had hopes for the cure of their child, not differentiating
7 between the trial and standard management, as described by Caldwell *et al.* [15] Finally, some
8 parents agreed to the participation of their child in a phase 3 randomized trial because they
9 considered that it would provide access to better follow-up than standard treatment as this has
10 also been reported in non-oncological protocols.[16-18] In our study, reading the information
11 document improved parental comprehension. Unfortunately, some of these documents are
12 difficult to read,[19,20] so it is important for investigating doctors to pay particular attention,
13 when writing such documents, to ensure that they are clear, as short as possible and
14 understandable by all. O’Lonegan et al. recently reported a novel approach in which visual
15 and audio media (multimedia) were used, rather than a paper-based written text document, to
16 make the information easier to comprehend.[21] However, this was a hypothetical research
17 study involving simple, low-risk procedures and may therefore not be representative of actual
18 research studies.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 As shown above, some of the elements of the research protocol were well understood, but not
39 by all the parents. So, how can the parents decide? Although not yet demonstrated in
40 pediatrics to our knowledge, quality of life is a crucial element in the decision of parents to
41 agree to or refuse the participation of their child in a randomized phase 3 trial. The willing of
42 a smaller amount of time spent in hospital and the smaller number of journeys for a research
43 protocol than for standard treatment was an element that appeared frequently in the decision-
44 making process. Recent studies have reported that logistic constraints are a major element in
45 the decisions of adult patients, [22,23] sometimes even outweighing benefits. In our study, the
46 parents took into account the benefits and constraints of inclusion to a much greater extent
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 than the risks specific to the research protocol, as indicated by their poor “recall” of the risks.
4
5 However, there may be several reasons for this recall failure. For example, having given their
6
7 consent for participation, the parents may minimize the impact of potential risks, focusing
8
9 instead on the possible benefits of participation. Other parents may try to protect themselves
10
11 psychologically by blocking out the largest risks. The parents may also feel that their child’s
12
13 illness poses a greater and more immediate threat, in terms of morbidity and mortality, than
14
15 the risks inherent to a clinical trial. These and other factors affect people’s perceptions of risk,
16
17 potentially accounting for the poor recall of risks specific to the randomized trial. Overall,
18
19 even if the decision was difficult for some of the parents, more than half felt that it was
20
21 logical. The decision seemed to be linked to the confidence of the parents in the investigating
22
23 doctor and their relationship with that doctor.[24] This confidence overcame the imbalance in
24
25 knowledge between the parents and the doctor.[5,11] By contrast, a lack of confidence in the
26
27 doctor may be associated with the decision being more difficult for the parents.[8] In previous
28
29 studies,[25-27] the way in which the investigating doctor presented the trial to the patient was
30
31 found to affect the likelihood of participation. In our study, the parents recognized that the
32
33 doctor played an important role in their decision, but they did never feel obliged to sign the
34
35 consent form.

36
37
38
39
40 What may appear to the investigating doctor to be a poor understanding of the research
41
42 protocol may actually correspond to the parents’ construction of the situation to render it
43
44 acceptable, thus allowing them to fulfill their role as protectors of their children. Given that it
45
46 is difficult to accept that there is uncertainty about the effectiveness of trial treatments and
47
48 assumptions that the experimental treatment will necessarily be superior, these responses
49
50 indicate that the parents seek hope and certainty in this uncertain situation in which they feel
51
52 threatened. Parents need to give their decision some meaning, by seeing it as being in the best
53
54 interests of their child.
55
56
57
58
59
60

1
2
3 In conclusion, most parents understand most of the elements of informed consent well.
4
5 However, knowledge is limited in some areas and improvements of information process are
6
7 required. Parents tend to underestimate risks specific to the randomized trial and the unproven
8
9 nature of the treatment is not well known or understood. Investigators should also
10
11 systematically ask the parents to reformulate the information they have been given to verify
12
13 that they have understood; this would also encourage active parental participation
14
15 in a two-way information exchange process.
16
17
18
19

20
21 **Acknowledgements:** We thank the parents who agreed to participate in this study, making
22
23 this work possible. We thank all the investigating doctors from the Société Française des
24
25 Cancers de l'Enfant (SFCE), the psychologists (Amélie de Haut de Sigy and Anne Charlotte
26
27 Foubert) and also, the clinical research assistants from all centers.
28

29
30 **Contributors:** HC, DD and FD conceived this study and HC obtained research funding. JM
31
32 T, NB and HC was in charge of all the data analyses. HC took the lead in reviewing the
33
34 literature and crosschecking references. HC, JMT drafted major portions of the initial
35
36 manuscript, whereas DD, FD helped refine it. The other authors CP, JLP, AA, HP were
37
38 investigators. HC, JMT, NB, DD, FD, VMC, LB, DO have seen and approved the submission
39
40 of this version of the manuscript and takes full responsibility for the manuscript.
41

42
43 **Funding:** This work received funding from a clinical research initiation contract (DRRC
44
45 APHP).
46

47
48 **Competing interests:** None.

49
50 **Data sharing statement:** No additional data are available.
51
52
53
54
55
56
57
58
59
60

References

1. Kodish E, Eder M, Noll RB, et al. Communication of randomization in childhood leukemia trials. *JAMA* 2004;**291**:470-475.
2. Kupst MJ, Patenaude AF, Walco GA, et al. Clinical trials in pediatric cancer: parental perspectives on informed consent. *J Pediatr Hematol Oncol* 2003;**25**:787-790.
3. Falagas ME, Korbila IP, Giannopoulou KP, et al. Informed consent: how much and what do patients understand? *Am J Surg* 2009;**198**:420-435.
4. Bergenmar M, Molin C, Wilking N, et al. Knowledge and understanding among cancer patients consenting to participate in clinical trials. *Eur J Cancer* 2008;**44**:2627-2633.
5. Chappuy H, Baruchel A, Leverger G, et al. Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia. *Arch Dis Child* 2010;**95**:800-804.
6. Miller VA, Drotar D, Burant C, et al. Clinician-parent communication during informed consent for pediatric leukemia trials. *J Pediatr Psychol* 2005;**30**:219-229.
7. Greenley RN, Drotar D, Zyzanski SJ, et al. Stability of parental understanding of random assignment in childhood leukemia trials: an empirical examination of informed consent. *J Clin Oncol* 2006;**24**:891-897.
8. Chappuy H, Doz F, Blanche S, et al. Parental consent in paediatric clinical research. *Arch Dis Child* 2006;**91**:112-116.
9. Wiley FM, Ruccione K, Moore IM, et al. Parents' perceptions of randomization in pediatric clinical trials. Children Cancer Group. *Cancer Pract* 1999;**7**:248-256.
10. Snowdon C, Garcia J, Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. *Soc Sci Med* 1997;**45**:1337-1355.

- 1
2
3 11. Eiser C, Davies H, Jenney M, et al. Mothers' attitudes to the randomized controlled
4
5 trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children. *Child Care*
6
7 *Health Dev* 2005;**31**:517-23.
- 8
9
10 12. Tait AR, Zikmund-Fisher BJ, Fagerlin A, et al. Effect of various risk/benefit trade-offs
11
12 on parents' understanding of a pediatric research study. *Pediatrics* 2010;**125**:e1475-
13
14 1482.
- 15
16 13. Weinfurt KP, Castel LD, Li Y, et al. The correlation between patient characteristics
17
18 and expectations of benefit from Phase I clinical trials. *Cancer* 2003;**98**:166-175.
- 19
20
21 14. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations
22
23 regarding phase I clinical trials. *J Clin Oncol* 2000;**18**:421-428. Erratum in: *J Clin*
24
25 *Oncol* 2000;**18**:1807.
- 26
27 15. Caldwell PH, Butow PN, Craig JC. Parents' attitudes to children's participation in
28
29 randomized controlled trials. *J Pediatr* 2003;**142**:554-559.
- 30
31
32 16. Pletsch PK, Stevens PE. Inclusion of children in clinical research: lessons learned
33
34 from mothers of diabetic children. *Clin Nurs Res* 2001;**10**:140-162.
- 35
36 17. Gammelgaard A, Knudsen LE, Bisgaard H. Perceptions of parents on the participation
37
38 of their infants in clinical research. *Arch Dis Child* 2006;**91**:977-980.
- 39
40
41 18. van Stuijvenberg M, Suur MH, de Vos S, et al. Informed consent, parental awareness,
42
43 and reasons for participating in a randomised controlled study. *Arch Dis Child*
44
45 1998;**79**:120-125.
- 46
47 19. Ménoni V, Lucas N, Leforestier JF, et al. Readability of the written study information
48
49 in pediatric research in France. *PLoS One* 2011;**6**:e18484.
- 50
51
52 20. Ménoni V, Lucas N, Leforestier JF, et al. The readability of information and consent
53
54 forms in clinical research in France. *PLoS One* 2010;**5**:e10576.
- 55
56
57
58
59
60

- 1
- 2
- 3 21. O'Lonegan TA, Forster-Harwood JE. Novel approach to parental permission and
- 4 child assent for research: improving comprehension. *Pediatrics* 2011;**127**:917-924.
- 5
- 6
- 7 22. Avis NE, Smith KW, Link CL, et al. Factors associated with participation in breast
- 8 cancer treatment clinical trials. *J Clin Oncol* 2006;**24**:1860-1867.
- 9
- 10
- 11 23. Cox K, McGarry J. Why patients don't take part in cancer clinical trials: An overview
- 12 of the literature. *Eur J Cancer Care* 2003;**12**:114-122.
- 13
- 14
- 15 24. Shilling V, Young B. How do parents experience being asked to enter a child in a
- 16 randomised controlled trial? *BMC Med Ethics* 2009;**10**:1.
- 17
- 18
- 19
- 20 25. Albrecht TL, Ruckdeschel JC, Riddle DL, et al. Communication and consumer
- 21 decision making about cancer clinical trials. *Patient Educ Couns* 2003;**50**:39-42.
- 22
- 23
- 24 26. Jenkins V, Fallowfield L, Solis-Trapala I, et al. Discussing randomized clinical trials
- 25 of cancer therapy: Evaluation of a Cancer Research UK training programme. *BMJ*
- 26 2005;**330**:400.
- 27
- 28
- 29 27. Harth SC, Thong YH. Parental perceptions and attitudes about informed consent in
- 30 clinical research involving children. *Soc Sci Med* 1995;**41**:1647-1651.
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Table 1: Description of the protocols studied according to the information leaflets

n	Disease	Main objective	Individual benefit	Randomization	Treatment duration	Specific risks	Alternative
17	Retinoblastoma	Conservative treatment, reduction of adverse effects	Conservative treatment, reduction of adverse effects	Standard chemotherapy vs new regimen	4-6 months	Auditory, renal, consciousness, pains in the limbs and jaw	Standard CT, enucleation
4	Ewing's sarcoma	R1: Reduction of toxicity R2: Evaluation of the efficacy	Lower renal toxicities	Standard CT vs new regimen	Not specified	Renal, decrease in sperm count/fertility++	Standard CT
7	High-risk neuroblastoma	Comparison of efficacy and toxicity of two high-dose chemotherapy regimens	Same efficacy, but fewer adverse effects	High-dose CT vs another high-dose CT	Not specified	Hepatic, thyroid, renal, auditory, endocrine, fertility	Standard CT
2	Low-grade glioma	Evaluation of the efficacy of a new chemotherapy combination	Best possible CT	Standard CT vs the new CT combination	81 weeks	Secondary induction of leukemia, hematologic and infectious toxicity	Standard CT
4	Standard-risk medulloblastoma	Evaluation of the efficacy of hyperfractionated RT and reduction of toxicity	Best possible RT, lower long term toxicity	Classical RT dose vs hyperfractionation	16 months	Neuro-cognitive impairment and endocrine problems	Classical fractionation of RT
5	Localized nephroblastoma	Assessment of the equivalence of two CT regimens	Same efficacy, but fewer adverse effects	Standard CT vs new regimen	25-30 weeks	Cardiac	Standard CT
1	Standard-risk hepatoblastoma	Reduction of toxicity	Same efficacy, but fewer adverse effects	Standard CT vs new regimen	3-5 months	Cardiac	Standard CT

n: number of children included in this study, CT: chemotherapy, RT: radiotherapy

Table 2: Questions asked during the interview addressing the level of understanding

No.	Concept	Question
1	Participation in a research protocol	"Is your child being treated as part of a research protocol?"
2	Aim of the protocol	"What is the aim of this protocol?"
3	Course of the protocol	"What is planned for your child in the framework of this protocol?"
4	Principle of randomization	"If you gave consent for a protocol in which two different treatments might be given, do you know how the treatment given to your child was chosen? If yes, how?"
5	Individual benefit	"What benefits do you expect your child to gain from participation in this protocol?"
6	Collective benefit	"Could you describe the possible benefits to other children of the participation of your child in this protocol?"
7	Risks	"What are the possible risks to your child of participating in this protocol?"
8	Alternatives	"If you had not consented to the participation of your child in this protocol, what care would your child have received?"
9	Voluntary nature of participation	"Was the participation of your child in this protocol voluntary?"
10	Duration of participation	"How long were you told that the participation of your child in this protocol would last?"
11	Freedom to withdraw from the project at any time	"Could you change your mind once the study had begun?"

Table 3: Characteristics of participating parents

Characteristic	Study group
Relationship to child (n, %)	
Father	20 (35)
Mother	37 (65)
Marital status (n, %)	
Married/living with partner	37 (92)
Divorced/separated	3 (8)
Parents' profession (n,%)	
High standing	11 (19)
Intermediate status	37 (65)
No profession	9 (16)
Mostly French-speaking (n,%)	
Yes	50 (86)
No	7 (14)
No. of children (n,%)	
1	11 (27.5)
2-3	21 (52.5)
4+	8 (20)
Patients' age (years)	
Mean (SD)	4.23 (4.5)
Median	1.93
Range	5 mo-15 yrs
First interview (n=40, 17 couples)	
Duration (minutes, mean(SD)/median, range)	51(17.8)/50.0, 20-90
Time since inclusion (days, mean(SD)/median, range)	34(6.3)/31.5, 23-50
Second interview (n=32, 7 couples)	
Duration (minutes, mean(SD)/median, range)	34(13.2)/35.0, 15-60
Time since inclusion (months, mean(SD)/median, range)	8.4(2.8)/8.0, 5-16



Table 4: Factors predictive of sufficient understanding of the information

Covariates		% items understood	<i>p</i>
Parents' profession	High standing	88.7 (SD 13.5)	0.09
	Intermediate status	86.0 (SD 15.8)	
	No profession	72.5 (SD 27.6)	
Mostly French-speaking	Yes	84.8 (SD 18.7)	0.03*
	No	61.9 (SD 29.6)	
Parents read the information sheet	Yes	88.7 (SD 14.8)	0.0025*
	No	68.5 (SD 24.6)	
Parents sought additional informations	Yes	84.5 (SD 18.1)	0.29
	No	77.2 (SD 25.1)	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Percentage of parents who understood each of the 11 items at M1 and M6

For peer review only



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



Parental comprehension of the benefits/risks of first line randomized clinical trials in children with solid tumors

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002733.R1
Article Type:	Research
Date Submitted by the Author:	27-Mar-2013
Complete List of Authors:	Chappuy, H�el�ene; H�opital Necker Enfants Malades, Pediatric emergency department Bouazza, Naim; APHP, Unit�e de Recherche Clinique Minard-Colin, Veronique; Institut Gustave Roussy, Department of Pediatric and Adolescent Oncology Patte, Catherine; Institut Gustave Roussy, Department of Pediatric and Adolescent Oncology Brugi�eres, Laurence; Institut Gustave Roussy, Department of Pediatric and Adolescent Oncology Landman-Parker, Judith; H�opital Armand Trousseau, Departement of Pediatric Oncology Auvrignon, Anne; H�opital Armand Trousseau, Departement of Pediatric Oncology Davous, Dominique; Association Apprivoiser l'absence, Cent pour Sang la Vie, Pacquement, H�el�ene; Institut Curie, Department of Pediatric Oncology Orbach, Daniel; Institut Curie, Department of Pediatric Oncology Tr�eluyer, Jean Marc; APHP, Pharmacology Doz, Fran�ois; Institut Curie, Department of Pediatric Oncology
Primary Subject Heading:	Ethics
Secondary Subject Heading:	Oncology, Paediatrics, Research methods
Keywords:	MEDICAL ETHICS, Paediatric oncology < ONCOLOGY, MEDICAL LAW

SCHOLARONE™
Manuscripts

1
2
3 **Parental comprehension of the benefits/risks of first line randomized clinical trials in**
4
5 **children with solid tumors**
6
7
8
9

10
11
12 **Key words:** child, neoplasm, randomized clinical trial, informed consent
13

14 **Words count:** 3117
15

16
17
18 **Authors:**
19

20 Chappuy, Hélène¹; Bouazza, Naim²; Minard-Colin, Veronique; Patte, Catherine³; Brugières,
21 Laurence³; Landman-Parker, Judith⁴; Auvrignon, Anne⁴; Davous, Dominique⁵; Pacquement,
22 Hélène⁶; Orbach, Daniel⁶; Tréluyer, Jean Marc⁷; Doz, François⁶
23
24
25
26
27
28

29 **Affiliations:**
30

- 31
32 1. Hôpital Necker Enfants Malades - Pediatric emergency department
33 Paris France
34
35 2. APHP - Unité de Recherche Clinique
36 paris France
37
38 3. Institut Gustave Roussy - Department of Pediatric and Adolescent Oncology
39 paris France
40
41 4. Hôpital Armand Trousseau - Departement of Pediatric Oncology
42 paris France
43
44 5. Association Apprivoiser l'absence, Cent pour Sang la Vie
45 paris France
46
47 6. Institut Curie - Department of Pediatric Oncology
48 paris France
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 7. APHP - Pharmacology
4

5 paris France
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Background: Patients and their parents must necessarily receive appropriate information to allow them to make truly autonomous decisions about participation in randomized clinical trials (RCTs). Few data are available that reflect the full spectrum of pediatric oncology clinical research. We analyzed parental understanding of informed consent (IC) information in first line RCTs including children with malignant solid tumors and to assess parents' needs for decision-making.

Methods: We carried out a prospective study including parents of children with malignant solid tumors whose consent was sought for the participation of their child in first line RCTs at three centers. Parents were questioned by a psychologist, independent of the pediatric oncology teams, using a semi-directed interview, one (M1) and six months (M6) after consent was sought.

Results: Forty first interviews (M1) were carried out. Eighteen parents (45%) did not understand the concept of randomization. Half of the parents could explain neither the aim of the clinical trial nor the potential benefit to their child of inclusion. Thirty-five parents (87.5%) expressed very few specific risks related to the trial. Twenty-eight parents (70%) were aware that they had the opportunity to refuse trial participation. Being mostly French-speaking ($p=0.03$) and the reading of the information sheet by the parents ($p=0.0025$) improved their understanding. The parental comprehension did not differ between M1 and M6. The principal factors underlying their decision were confidence in the medical team (39%), wish to access to the best treatment (37%) and the best quality of life (37%).

Conclusions: Despite medical explanations, parents have limited knowledge in some areas in first line RCTs and improvements of information process are required. The risks specific to the randomized trial are underestimated by parents and the unproven nature of the treatment is not well known or understood.

ARTICLE SUMMARY

Article focus

- How is the parental comprehension of the benefits/risks to their child with a solid tumor for the inclusion in a randomized phase 3 trial?
- Do perceived risks and benefits figure prominently in the parental decision about randomized phase 3 trial participation?

Key messages

- Most parents had understood the general aspects, by contrast, less than half the parents had correctly understood the more specific information such as the aims of the study, randomization, the various phases of treatment and the risks specific to the randomized trial.
- Parents tend to underestimate risks specific to the randomized trial and the unproven nature of the treatment is not well known or understood.
- Quality of life could be a crucial element in the decision of parents to agree to the participation of their child in a randomized phase 3 trial.

Strengths and limitations of this study

- We have data that reflect the full spectrum of pediatric oncology clinical research, including children with solid or brain tumors whereas most of the available pediatric data are related to research for newly diagnosed acute leukaemia.
- The parents were asked to participate in this study closely to having consented. Thus, the risk of recall bias was limited.

INTRODUCTION

Cancers occur before the age of 15 years in one in every 500 children and 1700 new cases are recorded each year for this age group in French registries (<http://sfce1.sfpediatrie.com/>).

Although global cure rates in pediatric cancers today achieve 80% in western countries, cancers are still the second leading cause of death in children between 1 and 15 years, after accidents. The optimization of treatment in pediatric oncology is desirable not only to continue to improve cure rates but also to decrease late effects. In this setting, randomized clinical trials (RCTs) to test new treatment options are essential in pediatric oncology.

The legislation require that parents give permission for a minor to enroll in a study, and it is important for researchers to increase their understanding of how parents arrive at a decision in this matter. [1-2] The balancing of potential risks and benefits could be critical for parental decisions about allowing their children to participate in research studies, and understanding how people weigh these factors is a key point. ML Boccia et al suggested that perceived risk and benefit figure prominently in a decision about research. [3] Patients and their parents must, therefore, necessarily receive appropriate information about the possible risks and the uncertain nature of the benefits of participation, to allow them to make truly autonomous decisions about participation in trials. They also require adequate information concerning crucial aspects of RCTs if they are to make an informed decision. However, published findings indicate that parents or patients often misunderstand the research to which they consent.[4-7] Furthermore, most of the available pediatric data on the information process in the context of phase 3 trials in oncology are related to research for newly diagnosed acute leukaemia, [8-10] few data are available that reflect the full spectrum of pediatric oncology clinical research, including children with solid or brain tumors.

1
2
3 The primary aim of this study was to analyze parental understanding of oral and written
4 information in RCTs including children with varied solid tumors. The secondary aim was to
5 assess the parents' statements in order to identify parental needs for decision-making.
6
7
8
9

10 11 12 **METHODS**

13 14 **Sample population**

15
16 This prospective study was carried out in the oncology departments of the three pediatric
17 oncology centers in the Parisian region: Institut Curie (Paris), Institut Gustave Roussy
18 (Villejuif), Hôpital Armand Trousseau (Paris). This study was approved by the appropriate
19 institutional review board (*Comité de Protection des Personnes Ile de France III Hôpital*
20 *Cochin*). The parents from these three centers who had been asked to give consent for the
21 participation of their child in a phase 3 randomized trial were included in this study, over a
22 one-year period. The doctors provided the parents with a copy of the information and consent
23 forms and a summary diagram of the various phases of the research protocol. To avoid bias
24 due to the assessment only of patients with a positive attitude to RCTs, we also included
25 parents of children that had declined to participate in the trial. The characteristics of these
26 randomized phase 3 trial protocols are described in table 1: most were trials aiming to
27 decrease the toxicity of treatment without affecting its efficacy. With the agreement of
28 physicians participating in the study, the physician seeking parental consent suggested
29 participation in our study to the parents. Non inclusion criteria included consent in a language
30 other than French. Families agreeing to participate were seen at the time of a planned
31 consultation during routine follow-up or at the time of a hospital admission in order to
32 minimise the additional constraints (time and travel) imposed on the parents.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 54 **Instrument**

1
2
3 The parents were seen twice, by a qualified psychologist: one month (M1) and six months
4 (M6) after they were asked to participate in a RCT. These interviews took place on site and
5 were recorded and transcribed in their entirety. The parents were allowed to express
6 themselves freely, in the framework of a semi-directed interview, in response to standardized
7 questions. The structure for the semi-directed interviews was developed in collaboration with
8 psychologists, the parent of a former patient representing a patients' association and some of
9 the investigating doctors from the centers participating in this study. This structure has been
10 validated in previous studies.[8,11] The interview covered various aspects of informed
11 consent (IC): we evaluated parental comprehension based on the 11 elements included in the
12 information sheet for each protocol. The questions asked to assess parental comprehension are
13 described in table 2.

14 We tried to identify elements predictive of a good understanding of the information provided
15 at the time at which consent was sought: parental socioprofessional category (high
16 standing/intermediate status/no profession), the principal language spoken, whether the
17 information document was read by the parents (yes/no), personal efforts to find information
18 (yes/no). We used the following questions to determine the reasons for which the parents had
19 given their consent: "How difficult was it to take the decision you took concerning the
20 participation of your child in this protocol?", "What were the principal elements underlying
21 your decision?", "Who do you feel took the final decision?" and "What do you expect from
22 the doctor?".

23 **Data analysis**

24 Each interview was independently coded by two psychologists, with the coding reviewed by a
25 pediatrician in cases of disagreement. Comprehension was classified as "complete", "partial"
26 or "null" for each element if all, some or none of the information sheet was expressed by the
27 parents. When considering risks, only those specific to the randomized trial were considered
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (table 1). To test the influence of covariates on comprehension, partial and complete
4
5 comprehension were pooled for each of the 11 elements and compared with the absence of
6
7 comprehension. We evaluated the influence of the covariates on the percentage of the
8
9 elements understood by the parents. A mixed effects model taking into account the subject
10
11 and items as crossed random effects was used to assessed the stability of parental
12
13 comprehension between the two interviews at M1 and M6. The data collected were put into
14
15 an Access database. The results are expressed as percentages, means and standard deviations,
16
17 medians and ranges. Chi² tests were carried out to compare qualitative values, *t* tests were
18
19 used to compare quantitative values (normality assumption was checked by quantile-quantile
20
21 plots and Shapiro-Wilks' test) and logistic regression analyses were carried out to assess the
22
23 influence of covariates. Agreement between the two psychologists was assessed with a
24
25 weighted kappa reliability test for ordered data.
26
27
28
29
30

31 RESULTS

32
33 During our study period, 53 families were approached to participate in a randomized clinical
34
35 trial. Forty families have been interviewed in our study. Our recruitment rate was 75%.
36
37 Thirteen families were non interviewed for several reasons: the delay of one month was
38
39 exceeded or the physicians have forgotten to propose our study.
40
41 We carried out 40 first interviews, including four with parents who declined participation in a
42
43 randomized phase 3 trial (one child with medulloblastoma, one with hepatoblastoma and two
44
45 with retinoblastoma). We interviewed 37 mothers and 20 fathers (17 couples, 3 men attending
46
47 alone and 20 women alone). We carried out 32 second interviews: four of the original
48
49 interviewees (or couples) declined a second interview and four others were lost to follow-up
50
51 for this study (management continued at another center). We interviewed 25 mothers and 14
52
53 fathers (7 couples, 7 men attending alone and 18 women alone). We considered the responses
54
55
56
57
58
59
60

1
2
3 of each of the couples as if they were individuals (i.e. below, “parent” refers to the mother,
4 father or couple interviewed). Regarding the values of weighted kappa obtained, 0.84 [95%
5 CI: 0.72 - 0.90] and 0.93 [95% CI: 0.85 - 0.96], for M1 and M6 respectively, there was a high
6 degree of agreement between the two psychologists about the coding of each interview. The
7 characteristics of the study group are summarized in Table 3.
8
9

10
11
12 In 64% of cases, information about the protocol had been provided by a single doctor, to both
13 parents simultaneously in 91% of these cases. Twenty-seven parents (68%) had reread the
14 information document. When asked if they had looked for information themselves, 13 parents
15 (32.5%) said they had not done so, while others (67.5%) having mostly (24/40) searched for
16 information about the disease rather than about the randomized clinical trial (7/40). Internet
17 was the principal source of information for these parents.
18
19

20 21 22 **Parental comprehension**

23
24 At the first interview, six parents (15%) confused consent for care with consent for research.
25 Each of these cases of confusion concerned a different protocol. Thirteen of the parents
26 (34.2%) did not know that randomization had occurred and five (13.2%) knew that
27 randomization existed but could not explain it clearly. When asked about the risks specific to
28 the randomized trial, four parents (10%) were unable to cite a single risk, 35 parents (87.5%)
29 were able to cite less than half the risks and one parent (2.5%) was able to cite more than half
30 the risks.
31
32

33
34 The results of the second interviews were compared with those of the first interview: the level
35 of parental comprehension did not differ markedly between M1 and M6 ($p=0.5$). Figure 1
36 summarizes the comprehension of the 11 elements described in the methods for the two
37 interviews.
38
39

40
41 As far as the benefit to their children was concerned, parents giving a different response from
42 that indicated in the information document (1st interview, 35% of parents/2nd interview, 11.1%
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of parents) expressed other aspects of the benefits anticipated for their child. Some felt there
4
5 was a benefit in terms of quality of life (less time spent in hospital, fewer displacements),
6
7 decreasing the amount of time for which their child would not attend school:
8

9
10 *“I think I would have had to stay here all day and he would have had to have two*
11 *sessions, but he wanted to go to school and that’s why he preferred to do it in one*
12 *go.”*, *“because the old treatment takes three days and this one only takes one day, so*
13 *for that reason alone, it’s better for him in my opinion.”*
14
15

16
17
18 Other parents had hopes of beneficial effects in terms of their child being cured:
19

20 *“Anyway, for him, if it’s beneficial he’s cured...and that’s the most important thing.”*
21
22

23 Some parents expressed notions of altruism:
24

25 *“Their aim and our aim are the same, because their goal is to progress in their*
26 *studies, to save children...”*, *“C. has benefited from what went before and so he*
27 *should help those who will come after him too.”*
28
29
30

31
32 Finally, some parents agreed to participation because they saw the research protocol as
33
34 providing access to better follow-up than they would have obtained with the standard
35
36 treatment:
37

38 *“We were told, relatively clearly, that children who followed research protocols... I’m*
39 *not saying that the others are neglected....but they are possibly followed a bit more*
40 *closely than children given the classic treatment, because of the phenomenon of data*
41 *collection for research.”*
42
43
44
45
46

47 If we look more closely at the responses of the four parents who refused to allow the
48
49 participation of their children in a research protocol, they had no notion (0/4) of an expected
50
51 benefit for their child (*“Yes but I don’t see why it’s beneficial for him, because in some ways*
52 *it’s still being evaluated”*).
53
54
55
56
57
58
59
60

1
2
3 Fluency in French ($p=0.03$) and reading the information notice ($p=0.0025$) were the only
4
5 covariates tested that significantly increased parental comprehension (table 4).
6

7 **Reasons for participation and physician's influence on the decision to participate**

8
9 When asked how they felt about taking this decision, 24 parents (60%) said that they felt it
10
11 was “a logical decision” and 10 parents (25%) said that they had found it difficult. The others
12
13 said that they weren't really “ready” to take a decision. In response to the question about the
14
15 elements guiding the decision, the most frequently given answers were confidence in the
16
17 medical team ($n=15$, 39%), access to the best possible treatment for the child ($n=14$, 37%) and
18
19 improvements in quality of life ($n=14$, 37%). Most of the parents ($n=34$, 85%) said that they
20
21 had taken the decision together, whereas the others had shared the task of decision-making
22
23 with the doctor ($n=1$, 2.5%) or with the child ($n=5$, 12.5%). The parents expected the
24
25 following of the doctor: communication (17/22, 77%), sincerity (11/22, 50%), availability
26
27 (11/22, 50%), humanity (7/22, 32%) and competence (7/22, 32%).
28
29
30
31
32
33

34 **DISCUSSION**

35
36 Ideally, parents giving consent for inclusion in a randomized clinical trial should have
37
38 understood all the elements required by law to protect the participant. In reality, parental
39
40 comprehension is highly variable and depends on the elements considered. Most parents had
41
42 understood the general aspects, such as the potential benefit to other children, the nature of
43
44 the study (a clinical trial), the notion of voluntary participation, the duration of participation,
45
46 the alternatives opened to them and the possibility of withdrawal at any time. By contrast,
47
48 less than half the parents had correctly understood the more specific information, such as the
49
50 aims of the study, randomization, the various phases of treatment and the risks specific to the
51
52 randomized trial. These results are similar to published findings.[4,5,8,12] For example, for
53
54 randomization in our study, some of the parents had views about the best “arm” for their
55
56
57
58
59
60

1
2
3 child: some preferred the standard treatment, which they considered to be less risky,[13]
4
5 whereas others were disappointed that their child was in the standard treatment arm because
6
7 they could not see the point of having consented to participation in the study.[14] We wished
8
9 to focus more specifically on parental comprehension of the potential (or expected) benefits to
10
11 their child of inclusion in a randomized phase 3 research protocol. Indeed, less than one third
12
13 of the parents were able to describe specifically the potential benefits to their child, as stated
14
15 in the information document. In a recent study, Tait *et al.* [15] showed, through the use of
16
17 scenarios, that only a quarter of the parents had fully understood the benefits to their child,
18
19 and comprehension was even lower for studies of treatments with efficacy levels similar to
20
21 those of the standard treatment, but lower expected toxicity. In our study, the parents
22
23 expressed other expectations, such as benefits in terms of quality of life (less time spent in
24
25 hospital, fewer displacements), resulting in fewer hours of absence from school. This aspect
26
27 of the perception of the benefits anticipated by parents has been identified before, in phase I
28
29 trials in adults.[16,17] Other parents had hopes for the cure of their child, not differentiating
30
31 between the trial and standard management, as described by Caldwell *et al.* [18] Finally, some
32
33 parents agreed to the participation of their child in a phase 3 randomized trial because they
34
35 considered that it would provide access to better follow-up than standard treatment as this has
36
37 also been reported in non-oncological protocols.[19-21] In our study, reading the information
38
39 document improved parental comprehension. Unfortunately, some of these documents are
40
41 difficult to read,[22,23] so it is important for investigating doctors to pay particular attention,
42
43 when writing such documents, to ensure that they are clear, as short as possible and
44
45 understandable by all. O'Lonergan *et al.* recently reported a novel approach in which visual
46
47 and audio media (multimedia) were used, rather than a paper-based written text document, to
48
49 make the information easier to comprehend.[24] However, this was a hypothetical research
50
51
52
53
54
55
56
57
58
59
60

1
2
3 study involving simple, low-risk procedures and may therefore not be representative of actual
4
5 research studies.

6
7 As shown above, some of the elements of the research protocol were well understood, but not
8
9 by all the parents. So, how can the parents decide? Although not yet demonstrated in
10
11 pediatrics to our knowledge, quality of life could be a crucial element in the decision of
12
13 parents to agree to or refuse the participation of their child in a randomized phase 3 trial. The
14
15 smaller amount of time spent in hospital and the smaller number of journeys for a research
16
17 protocol than for standard treatment was an element that appeared frequently in the decision-
18
19 making process. Recent studies have reported that logistic constraints are a major element in
20
21 the decisions of adult patients, [25,26] sometimes even outweighing benefits. In our study, the
22
23 parents took into account the benefits and constraints of inclusion to a much greater extent
24
25 than the risks specific to the research protocol, as indicated by their poor “recall” of the risks.
26
27 However, there may be several reasons for this recall failure. For example, having given their
28
29 consent for participation, the parents may minimize the impact of potential risks, focusing
30
31 instead on the possible benefits of participation. Other parents may try to protect themselves
32
33 psychologically by blocking out the largest risks. The parents may also feel that their child’s
34
35 illness poses a greater and more immediate threat, in terms of morbidity and mortality, than
36
37 the risks inherent to a clinical trial. These and other factors affect people’s perceptions of risk,
38
39 potentially accounting for the poor recall of risks specific to the randomized trial. [27]

40
41 Overall, even if the decision was difficult for some of the parents, more than half felt that it
42
43 was logical. The decision seemed to be linked to the confidence of the parents in the
44
45 investigating doctor and their relationship with that doctor.[28] This confidence overcame the
46
47 imbalance in knowledge between the parents and the doctor.[8,14] By contrast, a lack of
48
49 confidence in the doctor may be associated with the decision being more difficult for the
50
51 parents.[11] In previous studies,[29-31] the way in which the investigating doctor presented
52
53
54
55
56
57
58
59
60

1
2
3 the trial to the patient was found to affect the likelihood of participation. In our study, the
4
5 parents recognized that the doctor played an important role in their decision, but they did
6
7 never feel obliged to sign the consent form.
8

9
10 What may appear to the investigating doctor to be a poor understanding of the research
11
12 protocol may actually correspond to the parents' construction of the situation to render it
13
14 acceptable, thus allowing them to fulfill their role as protectors of their children. As suggested
15
16 by V. Shilling, [28] given that it is difficult to accept that there is uncertainty about the
17
18 effectiveness of trial treatments and assumptions that the experimental treatment will
19
20 necessarily be superior, these responses indicate that the parents seek hope and certainty in
21
22 this uncertain situation in which they feel threatened. Parents need to give their decision some
23
24 meaning, by seeing it as being in the best interests of their child.
25
26

27 In conclusion, most parents understand most of the elements of informed consent well.

28
29 However, knowledge is limited in some areas and improvements of information process are
30
31 required. Parents tend to underestimate risks specific to the randomized trial and the unproven
32
33 nature of the treatment is not well known or understood. Investigators should also
34
35 systematically ask the parents to reformulate the information they have been given to verify
36
37 that they have understood; this would also encourage active parental participation
38
39 in a two-way information exchange process.
40
41
42
43
44

45 **Acknowledgements:** We thank the parents who agreed to participate in this study, making
46
47 this work possible. We thank all the investigating doctors from the Société Française des
48
49 Cancers de l'Enfant (SFCE), the psychologists (Amélie de Haut de Sigy and Anne Charlotte
50
51 Foubert) and also, the clinical research assistants from all centers.
52

53
54 **Contributors:** HC, DD and FD conceived this study and HC obtained research funding. JM
55
56 T, NB and HC was in charge of all the data analyses. HC took the lead in reviewing the
57
58
59
60

1
2
3 literature and crosschecking references. HC, JMT drafted major portions of the initial
4
5 manuscript, whereas DD, FD helped refine it. The other authors CP, JLP, AA, HP were
6
7 investigators. HC, JMT, NB, DD, FD, VMC, LB, DO have seen and approved the submission
8
9 of this version of the manuscript and takes full responsibility for the manuscript.
10

11 **Funding:** This work received funding from a clinical research initiation contract (DRRC
12
13 APHP).
14

15
16 **Competing interests:** None.
17

18 **Data sharing statement:** No additional data are available.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Loi n°2004-806 du 9 août 2004 sur la recherche biomédicale. Code de la Santé Publique livre 1 titre 2. <http://www.legifrance.fr>
2. Directive 2001/20/EC of the European parliament and of the council of 4 april 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. <http://europa.eu.int>
3. Boccia ML, Campbell FA, Goldman BD, et al. Differential recall of consent information and parental decisions about enrolling children in research studies. *J Gen Psychol* 2009;**136**:91-108.
4. Kodish E, Eder M, Noll RB, et al. Communication of randomization in childhood leukemia trials. *JAMA* 2004;**291**:470-475.
5. Kupst MJ, Patenaude AF, Walco GA, et al. Clinical trials in pediatric cancer: parental perspectives on informed consent. *J Pediatr Hematol Oncol* 2003;**25**:787-790.
6. Falagas ME, Korbila IP, Giannopoulou KP, et al. Informed consent: how much and what do patients understand? *Am J Surg* 2009;**198**:420-435.
7. Bergenmar M, Molin C, Wilking N, et al. Knowledge and understanding among cancer patients consenting to participate in clinical trials. *Eur J Cancer* 2008;**44**:2627-2633.
8. Chappuy H, Baruchel A, Leverger G, et al. Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia. *Arch Dis Child* 2010;**95**:800-804.
9. Miller VA, Drotar D, Burant C, et al. Clinician-parent communication during informed consent for pediatric leukemia trials. *J Pediatr Psychol* 2005;**30**:219-229.

10. Greenley RN, Drotar D, Zyzanski SJ, et al. Stability of parental understanding of random assignment in childhood leukemia trials: an empirical examination of informed consent. *J Clin Oncol* 2006;**24**:891–897.
11. Chappuy H, Doz F, Blanche S, et al. Parental consent in paediatric clinical research. *Arch Dis Child* 2006;**91**:112-116.
12. Wiley FM, Ruccione K, Moore IM, et al. Parents' perceptions of randomization in pediatric clinical trials. Children Cancer Group. *Cancer Pract* 1999;**7**:248-256.
13. Snowdon C, Garcia J, Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. *Soc Sci Med* 1997;**45**:1337-1355.
14. Eiser C, Davies H, Jenney M, et al. Mothers' attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children. *Child Care Health Dev* 2005;**31**:517-23.
15. Tait AR, Zikmund-Fisher BJ, Fagerlin A, et al. Effect of various risk/benefit trade-offs on parents' understanding of a pediatric research study. *Pediatrics* 2010;**125**:e1475-1482.
16. Weinfurt KP, Castel LD, Li Y, et al. The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. *Cancer* 2003;**98**:166-175.
17. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. *J Clin Oncol* 2000;**18**:421-428. Erratum in: *J Clin Oncol* 2000;**18**:1807.
18. Caldwell PH, Butow PN, Craig JC. Parents' attitudes to children's participation in randomized controlled trials. *J Pediatr* 2003;**142**:554-559.
19. Pletsch PK, Stevens PE. Inclusion of children in clinical research: lessons learned from mothers of diabetic children. *Clin Nurs Res* 2001;**10**:140-162.

- 1
2
3 20. Gammelgaard A, Knudsen LE, Bisgaard H. Perceptions of parents on the participation of
4 their infants in clinical research. *Arch Dis Child* 2006;**91**:977-980.
5
6
7 21. van Stuijvenberg M, Suur MH, de Vos S, et al. Informed consent, parental awareness, and
8 reasons for participating in a randomised controlled study. *Arch Dis Child* 1998;**79**:120-
9 125.
10
11
12 22. Ménoni V, Lucas N, Leforestier JF, et al. Readability of the written study information in
13 pediatric research in France. *PLoS One* 2011;**6**:e18484.
14
15
16 23. Ménoni V, Lucas N, Leforestier JF, et al. The readability of information and consent
17 forms in clinical research in France. *PLoS One* 2010;**5**:e10576.
18
19
20 24. O'Lonergan TA, Forster-Harwood JE. Novel approach to parental permission and child
21 assent for research: improving comprehension. *Pediatrics* 2011;**127**:917-924.
22
23
24 25. Avis NE, Smith KW, Link CL, et al. Factors associated with participation in breast cancer
25 treatment clinical trials. *J Clin Oncol* 2006;**24**:1860-1867.
26
27
28 26. Cox K, McGarry J. Why patients don't take part in cancer clinical trials: An overview of
29 the literature. *Eur J Cancer Care* 2003;**12**:114-122.
30
31
32 27. Lloyd AJ. The extent of patients' understanding of the risk of treatments. *Qual Health*
33 *Care*. 2001 Sep;**10** Suppl 1:i14-8.
34
35
36 28. Shilling V, Young B. How do parents experience being asked to enter a child in a
37 randomised controlled trial? *BMC Med Ethics* 2009;**10**:1.
38
39
40 29. Albrecht TL, Ruckdeschel JC, Riddle DL, et al. Communication and consumer decision
41 making about cancer clinical trials. *Patient Educ Couns* 2003;**50**:39-42.
42
43
44 30. Jenkins V, Fallowfield L, Solis-Trapala I, et al. Discussing randomized clinical trials of
45 cancer therapy: Evaluation of a Cancer Research UK training programme. *BMJ*
46 2005;**330**:400.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

31. Harth SC, Thong YH. Parental perceptions and attitudes about informed consent in clinical research involving children. *Soc Sci Med* 1995;**41**:1647-1651.

For peer review only

Table 1: Description of the protocols studied according to the information leaflets

n	Disease	Main objective	Individual benefit	Randomization	Treatment duration	Specific risks	Alternative
17	Retinoblastoma	Conservative treatment, reduction of adverse effects	Conservative treatment, reduction of adverse effects	Standard chemotherapy vs new regimen	4-6 months	Auditory, renal, consciousness, pains in the limbs and jaw	Standard CT, enucleation
4	Ewing's sarcoma	R1: Reduction of toxicity R2: Evaluation of the efficacy	Lower renal toxicities	Standard CT vs new regimen	Not specified	Renal, decrease in sperm count/fertility++	Standard CT
7	High-risk neuroblastoma	Comparison of efficacy and toxicity of two high-dose chemotherapy regimens	Same efficacy, but fewer adverse effects	High-dose CT vs another high-dose CT	Not specified	Hepatic, thyroid, renal, auditory, endocrine, fertility	Standard CT
2	Low-grade glioma	Evaluation of the efficacy of a new chemotherapy combination	Best possible CT	Standard CT vs the new CT combination	81 weeks	Secondary induction of leukemia, hematologic and infectious toxicity	Standard CT
4	Standard-risk medulloblastoma	Evaluation of the efficacy of hyperfractionated RT and reduction of toxicity	Best possible RT, lower long term toxicity	Classical RT dose vs hyperfractionation	16 months	Neuro-cognitive impairment and endocrine problems	Classical fractionation of RT
5	Localized nephroblastoma	Assessment of the equivalence of two CT regimens	Same efficacy, but fewer adverse effects	Standard CT vs new regimen	25-30 weeks	Cardiac	Standard CT
1	Standard-risk hepatoblastoma	Reduction of toxicity	Same efficacy, but fewer adverse effects	Standard CT vs new regimen	3-5 months	Cardiac	Standard CT

n: number of children included in this study, CT: chemotherapy, RT: radiotherapy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2: Questions asked during the interview addressing the level of understanding

No.	Concept	Question
1	Participation in a research protocol	"Is your child being treated as part of a research protocol?"
2	Aim of the protocol	"What is the aim of this protocol?"
3	Course of the protocol	"What is planned for your child in the framework of this protocol?"
4	Principle of randomization	"If you gave consent for a protocol in which two different treatments might be given, do you know how the treatment given to your child was chosen? If yes, how?"
5	Individual benefit	"What benefits do you expect your child to gain from participation in this protocol?"
6	Collective benefit	"Could you describe the possible benefits to other children of the participation of your child in this protocol?"
7	Risks	"What are the possible risks to your child of participating in this protocol?"
8	Alternatives	"If you had not consented to the participation of your child in this protocol, what care would your child have received?"
9	Voluntary nature of participation	"Was the participation of your child in this protocol voluntary?"
10	Duration of participation	"How long were you told that the participation of your child in this protocol would last?"
11	Freedom to withdraw from the project at any time	"Could you change your mind once the study had begun?"

Table 3: Characteristics of participating parents

Characteristic	Study group
Relationship to child (n, %)	
Father	20 (35)
Mother	37 (65)
Marital status (n, %)	
Married/living with partner	37 (92)
Divorced/separated	3 (8)
Parents' profession (n,%)	
High standing	11 (19)
Intermediate status	37 (65)
No profession	9 (16)
Mostly French-speaking (n,%)	
Yes	50 (86)
No	7 (14)
No. of children (n,%)	
1	11 (27.5)
2-3	21 (52.5)
4+	8 (20)
Patients' age (years)	
Mean (SD)	4.23 (4.5)
Median	1.93
Range	5 mo-15 yrs
First interview (n=40, 17 couples)	
Duration (minutes, mean(SD)/median, range)	51(17.8)/50.0, 20-90
Time since inclusion (days, mean(SD)/median, range)	34(6.3)/31.5, 23-50
Second interview (n=32, 7 couples)	
Duration (minutes, mean(SD)/median, range)	34(13.2)/35.0, 15-60
Time since inclusion (months, mean(SD)/median, range)	8.4(2.8)/8.0, 5-16

Table 4: Factors predictive of sufficient understanding of the information

Covariates		% items understood	<i>p</i>
Parents' profession	H	88.7 (SD 13.5)	0.09
	High standing		
	Intermediate status	86.0 (SD 15.8)	
	No profession	72.5 (SD 27.6)	
Mostly French-speaking	Yes	84.8 (SD 18.7)	0.03*
	No	61.9 (SD 29.6)	
Parents read the information sheet	Yes	88.7 (SD 14.8)	0.0025*
	No	68.5 (SD 24.6)	
Parents sought additional informations	Yes	84.5 (SD 18.1)	0.29
	No	77.2 (SD 25.1)	

Figure 1: Percentage of parents who understood each of the 11 items at M1 and M6

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Parental comprehension of the benefits/risks of first line randomized clinical trials in children with solid tumors

Key words: child, neoplasm, randomized clinical trial, informed consent

Words count: 3117

For peer review only

Abstract

Background: Patients and their parents must necessarily receive appropriate information to allow them to make truly autonomous decisions about participation in randomized clinical trials (RCTs). Few data are available that reflect the full spectrum of pediatric oncology clinical research. We analyzed parental understanding of informed consent (IC) information in first line RCTs including children with malignant solid tumors and to assess parents' needs for decision-making.

Methods: We carried out a prospective study including parents of children with malignant solid tumors whose consent was sought for the participation of their child in first line RCTs at three centers. Parents were questioned by a psychologist, independent of the pediatric oncology teams, using a semi-directed interview, one (M1) and six months (M6) after consent was sought.

Results: Forty first interviews (M1) were carried out. Eighteen parents (45%) did not understand the concept of randomization. Half of the parents could explain neither the aim of the clinical trial nor the potential benefit to their child of inclusion. Thirty-five parents (87.5%) expressed very few specific risks related to the trial. Twenty-eight parents (70%) were aware that they had the opportunity to refuse trial participation. Being mostly French-speaking ($p=0.03$) and the reading of the information sheet by the parents ($p=0.0025$) improved their understanding. The parental comprehension did not differ between M1 and M6. The principal factors underlying their decision were confidence in the medical team (39%), wish to access to the best treatment (37%) and the best quality of life (37%).

Conclusions: Despite medical explanations, parents have limited knowledge in some areas in first line RCTs and improvements of information process are required. The risks specific to the randomized trial are underestimated by parents and the unproven nature of the treatment is not well known or understood.

ARTICLE SUMMARY

Article focus

- How is the parental comprehension of the benefits/risks to their child with a solid tumor for the inclusion in a randomized phase 3 trial?
- Do perceived risks and benefits figure prominently in the parental decision about randomized phase 3 trial participation?

Key messages

- Most parents had understood the general aspects, by contrast, less than half the parents had correctly understood the more specific information such as the aims of the study, randomization, the various phases of treatment and the risks specific to the randomized trial.
- Parents tend to underestimate risks specific to the randomized trial and the unproven nature of the treatment is not well known or understood.
- Quality of life **could be** a crucial element in the decision of parents to agree to the participation of their child in a randomized phase 3 trial.

Strengths and limitations of this study

- We have data that reflect the full spectrum of pediatric oncology clinical research, including children with solid or brain tumors whereas most of the available pediatric data are related to research for newly diagnosed acute leukaemia.
- The parents were asked to participate in this study closely to having consented. Thus, the risk of recall bias was limited.

INTRODUCTION

Cancers occur before the age of 15 years in one in every 500 children and 1700 new cases are recorded each year for this age group in French registries (<http://sfce1.sfpediatrie.com/>).

Although global cure rates in pediatric cancers today achieve 80% in western countries, cancers are still the second leading cause of death in children between 1 and 15 years, after accidents. The optimization of treatment in pediatric oncology is desirable not only to continue to improve cure rates but also to decrease late effects. In this setting, randomized clinical trials (RCTs) to test new treatment options are essential in pediatric oncology.

The legislation require that parents give permission for a minor to enroll in a study, and it is important for researchers to increase their understanding of how parents arrive at a decision in this matter. [1-2] The balancing of potential risks and benefits could be critical for parental decisions about allowing their children to participate in research studies, and understanding how people weigh these factors is a key point. ML Boccia et al suggested that perceived risk and benefit figure prominently in a decision about research. [3] Patients and their parents must, therefore, necessarily receive appropriate information about the possible risks and the uncertain nature of the benefits of participation, to allow them to make truly autonomous decisions about participation in trials. They also require adequate information concerning crucial aspects of RCTs if they are to make an informed decision. However, published findings indicate that parents or patients often misunderstand the research to which they consent.[4-7] Furthermore, most of the available pediatric data on the information process in the context of phase 3 trials in oncology are related to research for newly diagnosed acute leukaemia, [8-10] few data are available that reflect the full spectrum of pediatric oncology clinical research, including children with solid or brain tumors.

1
2
3 The primary aim of this study was to analyze parental understanding of oral and written
4 information in RCTs including children with varied solid tumors. The secondary aim was to
5 assess the parents' statements in order to identify parental needs for decision-making.
6
7
8
9

10 11 12 **METHODS**

13 14 **Sample population**

15
16 This prospective study was carried out in the oncology departments of the three pediatric
17 oncology centers in the Parisian region: Institut Curie (Paris), Institut Gustave Roussy
18 (Villejuif), Hôpital Armand Trousseau (Paris). This study was approved by the appropriate
19 institutional review board (*Comité de Protection des Personnes Ile de France III Hôpital*
20 *Cochin*). The parents from these three centers who had been asked to give consent for the
21 participation of their child in a phase 3 randomized trial were included in this study, over a
22 one-year period. The doctors provided the parents with a copy of the information and consent
23 forms and a summary diagram of the various phases of the research protocol. To avoid bias
24 due to the assessment only of patients with a positive attitude to RCTs, we also included
25 parents of children that had declined to participate in the trial. The characteristics of these
26 randomized phase 3 trial protocols are described in table 1: most were trials aiming to
27 decrease the toxicity of treatment without affecting its efficacy. With the agreement of
28 physicians participating in the study, the physician seeking parental consent suggested
29 participation in our study to the parents. Non inclusion criteria included consent in a language
30 other than French. Families agreeing to participate were seen at the time of a planned
31 consultation during routine follow-up or at the time of a hospital admission in order to
32 minimise the additional constraints (time and travel) imposed on the parents.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 54 **Instrument**

55
56
57
58
59
60

1
2
3 The parents were seen twice, by a qualified psychologist: one month (M1) and six months
4
5 (M6) after they were asked to participate in a RCT. These interviews took place on site and
6
7 were recorded and transcribed in their entirety. The parents were allowed to express
8
9 themselves freely, in the framework of a semi-directed interview, in response to standardized
10
11 questions. The structure for the semi-directed interviews was developed in collaboration with
12
13 psychologists, the parent of a former patient representing a patients' association and some of
14
15 the investigating doctors from the centers participating in this study. This structure has been
16
17 validated in previous studies.[8,11] The interview covered various aspects of informed
18
19 consent (IC): we evaluated parental comprehension based on the 11 elements included in the
20
21 information sheet for each protocol. The questions asked to assess parental comprehension are
22
23 described in table 2.
24
25

26
27 We tried to identify elements predictive of a good understanding of the information provided
28
29 at the time at which consent was sought: parental socioprofessional category (high
30
31 standing/intermediate status/no profession), the principal language spoken, whether the
32
33 information document was read by the parents (yes/no), personal efforts to find information
34
35 (yes/no). We used the following questions to determine the reasons for which the parents had
36
37 given their consent: "How difficult was it to take the decision you took concerning the
38
39 participation of your child in this protocol?", "What were the principal elements underlying
40
41 your decision?", "Who do you feel took the final decision?" and "What do you expect from
42
43 the doctor?".
44
45

46 47 **Data analysis**

48
49 Each interview was independently coded by two psychologists, with the coding reviewed by a
50
51 pediatrician in cases of disagreement. Comprehension was classified as "complete", "partial"
52
53 or "null" for each element if all, some or none of the information sheet was expressed by the
54
55 parents. When considering risks, only those specific to the randomized trial were considered
56
57
58
59
60

1
2
3 (table 1). To test the influence of covariates on comprehension, partial and complete
4
5 comprehension were pooled for each of the 11 elements and compared with the absence of
6
7 comprehension. We evaluated the influence of the covariates on the percentage of the
8
9 elements understood by the parents. A mixed effects model taking into account the subject
10
11 and items as crossed random effects was used to assessed the stability of parental
12
13 comprehension between the two interviews at M1 and M6. The data collected were put into
14
15 an Access database. The results are expressed as percentages, means and standard deviations,
16
17 medians and ranges. Chi² tests were carried out to compare qualitative values, *t* tests were
18
19 used to compare quantitative values (normality assumption was checked by quantile-quantile
20
21 plots and Shapiro-Wilks' test) and logistic regression analyses were carried out to assess the
22
23 influence of covariates. Agreement between the two psychologists was assessed with a
24
25 weighted kappa reliability test for ordered data.
26
27
28
29
30
31

32 RESULTS

33
34 During our study period, 53 families were approached to participate in a randomized clinical
35
36 trial. Forty families have been interviewed in our study. Our recruitment rate was 75%.

37
38 Thirteen families were non interviewed for several reasons: the delay of one month was
39
40 exceeded or the physicians have forgotten to propose our study.
41

42
43 We carried out 40 first interviews, including four with parents who declined participation in a
44
45 randomized phase 3 trial (one child with medulloblastoma, one with hepatoblastoma and two
46
47 with retinoblastoma). We interviewed 37 mothers and 20 fathers (17 couples, 3 men attending
48
49 alone and 20 women alone). We carried out 32 second interviews: four of the original
50
51 interviewees (or couples) declined a second interview and four others were lost to follow-up
52
53 for this study (management continued at another center). We interviewed 25 mothers and 14
54
55 fathers (7 couples, 7 men attending alone and 18 women alone). We considered the responses
56
57
58
59
60

1
2
3 of each of the couples as if they were individuals (i.e. below, “parent” refers to the mother,
4 father or couple interviewed). Regarding the values of weighted kappa obtained, 0.84 [95%
5 CI: 0.72 - 0.90] and 0.93 [95% CI: 0.85 - 0.96], for M1 and M6 respectively, there was a high
6 degree of agreement between the two psychologists about the coding of each interview. The
7 characteristics of the study group are summarized in Table 3.
8
9

10
11
12 In 64% of cases, information about the protocol had been provided by a single doctor, to both
13 parents simultaneously in 91% of these cases. Twenty-seven parents (68%) had reread the
14 information document. When asked if they had looked for information themselves, 13 parents
15 (32.5%) said they had not done so, while others (67.5%) having mostly (24/40) searched for
16 information about the disease rather than about the randomized clinical trial (7/40). Internet
17 was the principal source of information for these parents.
18
19

20 21 22 **Parental comprehension**

23
24 At the first interview, six parents (15%) confused consent for care with consent for research.
25 Each of these cases of confusion concerned a different protocol. Thirteen of the parents
26 (34.2%) did not know that randomization had occurred and five (13.2%) knew that
27 randomization existed but could not explain it clearly. When asked about the risks specific to
28 the randomized trial, four parents (10%) were unable to cite a single risk, 35 parents (87.5%)
29 were able to cite less than half the risks and one parent (2.5%) was able to cite more than half
30 the risks.
31
32

33
34 The results of the second interviews were compared with those of the first interview: the level
35 of parental comprehension did not differ markedly between M1 and M6 ($p=0.5$). Figure 1
36 summarizes the comprehension of the 11 elements described in the methods for the two
37 interviews.
38
39

40
41 As far as the benefit to their children was concerned, parents giving a different response from
42 that indicated in the information document (1st interview, 35% of parents/2nd interview, 11.1%
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of parents) expressed other aspects of the benefits anticipated for their child. Some felt there
4
5 was a benefit in terms of quality of life (less time spent in hospital, fewer displacements),
6
7 decreasing the amount of time for which their child would not attend school:
8

9
10 *“I think I would have had to stay here all day and he would have had to have two*
11 *sessions, but he wanted to go to school and that’s why he preferred to do it in one*
12 *go.”*, *“because the old treatment takes three days and this one only takes one day, so*
13 *for that reason alone, it’s better for him in my opinion.”*.
14
15
16
17

18 Other parents had hopes of beneficial effects in terms of their child being cured:
19

20 *“Anyway, for him, if it’s beneficial he’s cured...and that’s the most important thing.”*
21
22

23 Some parents expressed notions of altruism:
24

25 *“Their aim and our aim are the same, because their goal is to progress in their*
26 *studies, to save children...”*, *“C. has benefited from what went before and so he*
27 *should help those who will come after him too.”*
28
29
30
31

32 Finally, some parents agreed to participation because they saw the research protocol as
33
34 providing access to better follow-up than they would have obtained with the standard
35
36 treatment:
37

38 *“We were told, relatively clearly, that children who followed research protocols... I’m*
39 *not saying that the others are neglected....but they are possibly followed a bit more*
40 *closely than children given the classic treatment, because of the phenomenon of data*
41 *collection for research.”*
42
43
44
45
46

47 If we look more closely at the responses of the four parents who refused to allow the
48
49 participation of their children in a research protocol, they had no notion (0/4) of an expected
50
51 benefit for their child (*“Yes but I don’t see why it’s beneficial for him, because in some ways*
52 *it’s still being evaluated”*).
53
54
55
56
57
58
59
60

1
2
3 Fluency in French ($p=0.03$) and reading the information notice ($p=0.0025$) were the only
4
5 covariates tested that significantly increased parental comprehension (table 4).
6

7 **Reasons for participation and physician's influence on the decision to participate**

8
9
10 When asked how they felt about taking this decision, 24 parents (60%) said that they felt it
11
12 was “a logical decision” and 10 parents (25%) said that they had found it difficult. The others
13
14 said that they weren't really “ready” to take a decision. In response to the question about the
15
16 elements guiding the decision, the most frequently given answers were confidence in the
17
18 medical team ($n=15$, 39%), access to the best possible treatment for the child ($n=14$, 37%) and
19
20 improvements in quality of life ($n=14$, 37%). Most of the parents ($n=34$, 85%) said that they
21
22 had taken the decision together, whereas the others had shared the task of decision-making
23
24 with the doctor ($n=1$, 2.5%) or with the child ($n=5$, 12.5%). The parents expected the
25
26 following of the doctor: communication (17/22, 77%), sincerity (11/22, 50%), availability
27
28 (11/22, 50%), humanity (7/22, 32%) and competence (7/22, 32%).
29
30
31
32
33

34 **DISCUSSION**

35
36 Ideally, parents giving consent for inclusion in a randomized clinical trial should have
37
38 understood all the elements required by law to protect the participant. In reality, parental
39
40 comprehension is highly variable and depends on the elements considered. Most parents had
41
42 understood the general aspects, such as the potential benefit to other children, the nature of
43
44 the study (a clinical trial), the notion of voluntary participation, the duration of participation,
45
46 the alternatives opened to them and the possibility of withdrawal at any time. By contrast,
47
48 less than half the parents had correctly understood the more specific information, such as the
49
50 aims of the study, randomization, the various phases of treatment and the risks specific to the
51
52 randomized trial. These results are similar to published findings.[4,5,8,12] For example, for
53
54 randomization in our study, some of the parents had views about the best “arm” for their
55
56
57
58
59
60

1
2
3 child: some preferred the standard treatment, which they considered to be less risky,[13]
4
5 whereas others were disappointed that their child was in the standard treatment arm because
6
7 they could not see the point of having consented to participation in the study.[14] We wished
8
9 to focus more specifically on parental comprehension of the potential (or expected) benefits to
10
11 their child of inclusion in a randomized phase 3 research protocol. Indeed, less than one third
12
13 of the parents were able to describe specifically the potential benefits to their child, as stated
14
15 in the information document. In a recent study, Tait *et al.* [15] showed, through the use of
16
17 scenarios, that only a quarter of the parents had fully understood the benefits to their child,
18
19 and comprehension was even lower for studies of treatments with efficacy levels similar to
20
21 those of the standard treatment, but lower expected toxicity. In our study, the parents
22
23 expressed other expectations, such as benefits in terms of quality of life (less time spent in
24
25 hospital, fewer displacements), resulting in fewer hours of absence from school. This aspect
26
27 of the perception of the benefits anticipated by parents has been identified before, in phase I
28
29 trials in adults.[16,17] Other parents had hopes for the cure of their child, not differentiating
30
31 between the trial and standard management, as described by Caldwell *et al.* [18] Finally, some
32
33 parents agreed to the participation of their child in a phase 3 randomized trial because they
34
35 considered that it would provide access to better follow-up than standard treatment as this has
36
37 also been reported in non-oncological protocols.[19-21] In our study, reading the information
38
39 document improved parental comprehension. Unfortunately, some of these documents are
40
41 difficult to read,[22,23] so it is important for investigating doctors to pay particular attention,
42
43 when writing such documents, to ensure that they are clear, as short as possible and
44
45 understandable by all. O'Lonergan *et al.* recently reported a novel approach in which visual
46
47 and audio media (multimedia) were used, rather than a paper-based written text document, to
48
49 make the information easier to comprehend.[24] However, this was a hypothetical research
50
51
52
53
54
55
56
57
58
59
60

1
2
3 study involving simple, low-risk procedures and may therefore not be representative of actual
4
5 research studies.

6
7 As shown above, some of the elements of the research protocol were well understood, but not
8
9 by all the parents. So, how can the parents decide? Although not yet demonstrated in
10
11 pediatrics to our knowledge, quality of life **could be** a crucial element in the decision of
12
13 parents to agree to or refuse the participation of their child in a randomized phase 3 trial. **The**
14
15 **smaller** amount of time spent in hospital and the smaller number of journeys for a research
16
17 protocol than for standard treatment was an element that appeared frequently in the decision-
18
19 making process. Recent studies have reported that logistic constraints are a major element in
20
21 the decisions of adult patients, [25,26] sometimes even outweighing benefits. In our study, the
22
23 parents took into account the benefits and constraints of inclusion to a much greater extent
24
25 than the risks specific to the research protocol, as indicated by their poor “recall” of the risks.
26
27 However, there may be several reasons for this recall failure. For example, having given their
28
29 consent for participation, the parents may minimize the impact of potential risks, focusing
30
31 instead on the possible benefits of participation. Other parents may try to protect themselves
32
33 psychologically by blocking out the largest risks. The parents may also feel that their child’s
34
35 illness poses a greater and more immediate threat, in terms of morbidity and mortality, than
36
37 the risks inherent to a clinical trial. These and other factors affect people’s perceptions of risk,
38
39 potentially accounting for the poor recall of risks specific to the randomized trial. [27]
40
41 Overall, even if the decision was difficult for some of the parents, more than half felt that it
42
43 was logical. The decision seemed to be linked to the confidence of the parents in the
44
45 investigating doctor and their relationship with that doctor.[28] This confidence overcame the
46
47 imbalance in knowledge between the parents and the doctor.[8,14] By contrast, a lack of
48
49 confidence in the doctor may be associated with the decision being more difficult for the
50
51 parents.[11] In previous studies,[29-31] the way in which the investigating doctor presented
52
53
54
55
56
57
58
59
60

1
2
3 the trial to the patient was found to affect the likelihood of participation. In our study, the
4
5 parents recognized that the doctor played an important role in their decision, but they did
6
7 never feel obliged to sign the consent form.
8

9
10 What may appear to the investigating doctor to be a poor understanding of the research
11
12 protocol may actually correspond to the parents' construction of the situation to render it
13
14 acceptable, thus allowing them to fulfill their role as protectors of their children. As suggested
15
16 by V. Shilling, [28] given that it is difficult to accept that there is uncertainty about the
17
18 effectiveness of trial treatments and assumptions that the experimental treatment will
19
20 necessarily be superior, these responses indicate that the parents seek hope and certainty in
21
22 this uncertain situation in which they feel threatened. Parents need to give their decision some
23
24 meaning, by seeing it as being in the best interests of their child.
25
26

27 In conclusion, most parents understand most of the elements of informed consent well.
28

29 However, knowledge is limited in some areas and improvements of information process are
30
31 required. Parents tend to underestimate risks specific to the randomized trial and the unproven
32
33 nature of the treatment is not well known or understood. Investigators should also
34
35 systematically ask the parents to reformulate the information they have been given to verify
36
37 that they have understood; this would also encourage active parental participation
38
39 in a two-way information exchange process.
40
41
42
43
44

45 **Acknowledgements:** We thank the parents who agreed to participate in this study, making
46
47 this work possible. We thank all the investigating doctors from the Société Française des
48
49 Cancers de l'Enfant (SFCE), the psychologists (Amélie de Haut de Sigy and Anne Charlotte
50
51 Foubert) and also, the clinical research assistants from all centers.
52
53

54 **Contributors:** HC, DD and FD conceived this study and HC obtained research funding. JM
55
56 T, NB and HC was in charge of all the data analyses. HC took the lead in reviewing the
57
58
59
60

1
2
3 literature and crosschecking references. HC, JMT drafted major portions of the initial
4
5 manuscript, whereas DD, FD helped refine it. The other authors CP, JLP, AA, HP were
6
7 investigators. HC, JMT, NB, DD, FD, VMC, LB, DO have seen and approved the submission
8
9 of this version of the manuscript and takes full responsibility for the manuscript.
10

11 **Funding:** This work received funding from a clinical research initiation contract (DRRC
12
13 APHP).
14

15
16 **Competing interests:** None.
17

18 **Data sharing statement:** No additional data are available.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Loi n°2004-806 du 9 août 2004 sur la recherche biomédicale. Code de la Santé Publique livre 1 titre 2. <http://www.legifrance.fr>
2. Directive 2001/20/EC of the European parliament and of the council of 4 april 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. <http://europa.eu.int>
3. Boccia ML, Campbell FA, Goldman BD, et al. Differential recall of consent information and parental decisions about enrolling children in research studies. *J Gen Psychol* 2009;136:91-108.
4. Kodish E, Eder M, Noll RB, et al. Communication of randomization in childhood leukemia trials. *JAMA* 2004;291:470-475.
5. Kupst MJ, Patenaude AF, Walco GA, et al. Clinical trials in pediatric cancer: parental perspectives on informed consent. *J Pediatr Hematol Oncol* 2003;25:787-790.
6. Falagas ME, Korbila IP, Giannopoulou KP, et al. Informed consent: how much and what do patients understand? *Am J Surg* 2009;198:420-435.
7. Bergenmar M, Molin C, Wilking N, et al. Knowledge and understanding among cancer patients consenting to participate in clinical trials. *Eur J Cancer* 2008;44:2627-2633.
8. Chappuy H, Baruchel A, Leverger G, et al. Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia. *Arch Dis Child* 2010;95:800-804.
9. Miller VA, Drotar D, Burant C, et al. Clinician-parent communication during informed consent for pediatric leukemia trials. *J Pediatr Psychol* 2005;30:219-229.

10. Greenley RN, Drotar D, Zyzanski SJ, et al. Stability of parental understanding of random assignment in childhood leukemia trials: an empirical examination of informed consent. *J Clin Oncol* 2006;**24**:891–897.
11. Chappuy H, Doz F, Blanche S, et al. Parental consent in paediatric clinical research. *Arch Dis Child* 2006;**91**:112-116.
12. Wiley FM, Ruccione K, Moore IM, et al. Parents' perceptions of randomization in pediatric clinical trials. Children Cancer Group. *Cancer Pract* 1999;**7**:248-256.
13. Snowdon C, Garcia J, Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. *Soc Sci Med* 1997;**45**:1337-1355.
14. Eiser C, Davies H, Jenney M, et al. Mothers' attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children. *Child Care Health Dev* 2005;**31**:517-23.
15. Tait AR, Zikmund-Fisher BJ, Fagerlin A, et al. Effect of various risk/benefit trade-offs on parents' understanding of a pediatric research study. *Pediatrics* 2010;**125**:e1475-1482.
16. Weinfurt KP, Castel LD, Li Y, et al. The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. *Cancer* 2003;**98**:166-175.
17. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. *J Clin Oncol* 2000;**18**:421-428. Erratum in: *J Clin Oncol* 2000;**18**:1807.
18. Caldwell PH, Butow PN, Craig JC. Parents' attitudes to children's participation in randomized controlled trials. *J Pediatr* 2003;**142**:554-559.
19. Pletsch PK, Stevens PE. Inclusion of children in clinical research: lessons learned from mothers of diabetic children. *Clin Nurs Res* 2001;**10**:140-162.

- 1
2
3 20. Gammelgaard A, Knudsen LE, Bisgaard H. Perceptions of parents on the participation of
4
5 their infants in clinical research. *Arch Dis Child* 2006;**91**:977-980.
6
7 21. van Stuijvenberg M, Suur MH, de Vos S, et al. Informed consent, parental awareness, and
8
9 reasons for participating in a randomised controlled study. *Arch Dis Child* 1998;**79**:120-
10
11 125.
12
13 22. Ménoni V, Lucas N, Leforestier JF, et al. Readability of the written study information in
14
15 pediatric research in France. *PLoS One* 2011;**6**:e18484.
16
17 23. Ménoni V, Lucas N, Leforestier JF, et al. The readability of information and consent
18
19 forms in clinical research in France. *PLoS One* 2010;**5**:e10576.
20
21 24. O'Lonergan TA, Forster-Harwood JE. Novel approach to parental permission and child
22
23 assent for research: improving comprehension. *Pediatrics* 2011;**127**:917-924.
24
25 25. Avis NE, Smith KW, Link CL, et al. Factors associated with participation in breast cancer
26
27 treatment clinical trials. *J Clin Oncol* 2006;**24**:1860-1867.
28
29 26. Cox K, McGarry J. Why patients don't take part in cancer clinical trials: An overview of
30
31 the literature. *Eur J Cancer Care* 2003;**12**:114-122.
32
33 27. Lloyd AJ. The extent of patients' understanding of the risk of treatments. *Qual Health*
34
35 *Care*. 2001 Sep;**10** Suppl 1:i14-8.
36
37
38
39 28. Shilling V, Young B. How do parents experience being asked to enter a child in a
40
41 randomised controlled trial? *BMC Med Ethics* 2009;**10**:1.
42
43 29. Albrecht TL, Ruckdeschel JC, Riddle DL, et al. Communication and consumer decision
44
45 making about cancer clinical trials. *Patient Educ Couns* 2003;**50**:39-42.
46
47 30. Jenkins V, Fallowfield L, Solis-Trapala I, et al. Discussing randomized clinical trials of
48
49 cancer therapy: Evaluation of a Cancer Research UK training programme. *BMJ*
50
51 2005;**330**:400.
52
53
54
55
56
57
58
59
60

- 1
2
3 31. Harth SC, Thong YH. Parental perceptions and attitudes about informed consent in
4
5 clinical research involving children. *Soc Sci Med* 1995;**41**:1647-1651.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1: Description of the protocols studied according to the information leaflets

n	Disease	Main objective	Individual benefit	Randomization	Treatment duration	Specific risks	Alternative
17	Retinoblastoma	Conservative treatment, reduction of adverse effects	Conservative treatment, reduction of adverse effects	Standard chemotherapy vs new regimen	4-6 months	Auditory, renal, consciousness, pains in the limbs and jaw	Standard CT, enucleation
4	Ewing's sarcoma	R1: Reduction of toxicity R2: Evaluation of the efficacy	Lower renal toxicities	Standard CT vs new regimen	Not specified	Renal, decrease in sperm count/fertility++	Standard CT
7	High-risk neuroblastoma	Comparison of efficacy and toxicity of two high-dose chemotherapy regimens	Same efficacy, but fewer adverse effects	High-dose CT vs another high-dose CT	Not specified	Hepatic, thyroid, renal, auditory, endocrine, fertility	Standard CT
2	Low-grade glioma	Evaluation of the efficacy of a new chemotherapy combination	Best possible CT	Standard CT vs the new CT combination	81 weeks	Secondary induction of leukemia, hematologic and infectious toxicity	Standard CT
4	Standard-risk medulloblastoma	Evaluation of the efficacy of hyperfractionated RT and reduction of toxicity	Best possible RT, lower long term toxicity	Classical RT dose vs hyperfractionation	16 months	Neuro-cognitive impairment and endocrine problems	Classical fractionation of RT
5	Localized nephroblastoma	Assessment of the equivalence of two CT regimens	Same efficacy, but fewer adverse effects	Standard CT vs new regimen	25-30 weeks	Cardiac	Standard CT
1	Standard-risk hepatoblastoma	Reduction of toxicity	Same efficacy, but fewer adverse effects	Standard CT vs new regimen	3-5 months	Cardiac	Standard CT

n: number of children included in this study, CT: chemotherapy, RT: radiotherapy

Table 2: Questions asked during the interview addressing the level of understanding

No.	Concept	Question
1	Participation in a research protocol	"Is your child being treated as part of a research protocol?"
2	Aim of the protocol	"What is the aim of this protocol?"
3	Course of the protocol	"What is planned for your child in the framework of this protocol?"
4	Principle of randomization	"If you gave consent for a protocol in which two different treatments might be given, do you know how the treatment given to your child was chosen? If yes, how?"
5	Individual benefit	"What benefits do you expect your child to gain from participation in this protocol?"
6	Collective benefit	"Could you describe the possible benefits to other children of the participation of your child in this protocol?"
7	Risks	"What are the possible risks to your child of participating in this protocol?"
8	Alternatives	"If you had not consented to the participation of your child in this protocol, what care would your child have received?"
9	Voluntary nature of participation	"Was the participation of your child in this protocol voluntary?"
10	Duration of participation	"How long were you told that the participation of your child in this protocol would last?"
11	Freedom to withdraw from the project at any time	"Could you change your mind once the study had begun?"

Table 3: Characteristics of participating parents

Characteristic	Study group
Relationship to child (n, %)	
Father	20 (35)
Mother	37 (65)
Marital status (n, %)	
Married/living with partner	37 (92)
Divorced/separated	3 (8)
Parents' profession (n,%)	
High standing	11 (19)
Intermediate status	37 (65)
No profession	9 (16)
Mostly French-speaking (n,%)	
Yes	50 (86)
No	7 (14)
No. of children (n,%)	
1	11 (27.5)
2-3	21 (52.5)
4+	8 (20)
Patients' age (years)	
Mean (SD)	4.23 (4.5)
Median	1.93
Range	5 mo-15 yrs
First interview (n=40, 17 couples)	
Duration (minutes, mean(SD)/median, range)	51(17.8)/50.0, 20-90
Time since inclusion (days, mean(SD)/median, range)	34(6.3)/31.5, 23-50
Second interview (n=32, 7 couples)	
Duration (minutes, mean(SD)/median, range)	34(13.2)/35.0, 15-60
Time since inclusion (months, mean(SD)/median, range)	8.4(2.8)/8.0, 5-16

Table 4: Factors predictive of sufficient understanding of the information


Covariates		% items understood	<i>p</i>
Parents' profession	High standing	88.7 (SD 13.5)	0.09
	Intermediate status	86.0 (SD 15.8)	
	No profession	72.5 (SD 27.6)	
Mostly French-speaking	Yes	84.8 (SD 18.7)	0.03*
	No	61.9 (SD 29.6)	
Parents read the information sheet	Yes	88.7 (SD 14.8)	0.0025*
	No	68.5 (SD 24.6)	
Parents sought additional informations	Yes	84.5 (SD 18.1)	0.29
	No	77.2 (SD 25.1)	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Percentage of parents who understood each of the 11 items at M1 and M6

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Percentage of parents who understood each of the 11 items at M1 and M6
127x90mm (300 x 300 DPI)

view only